Technical Analysis for TRVN - Trevena, Inc.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
F | 0.55 | 0.00% | 0.00 |
Earnings due: Mar 28
*** please verify all earnings dates ***ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Down | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
20 DMA Resistance | Bearish | 0.00% | |
Bollinger Band Squeeze | Range Contraction | 0.00% | |
Oversold Stochastic | Weakness | 0.00% | |
Bollinger Band Squeeze | Range Contraction | 0.00% | |
Narrow Range Bar | Range Contraction | 0.00% | |
Oversold Stochastic | Weakness | 0.00% | |
Bollinger Band Squeeze | Range Contraction | -2.48% | |
NR7 | Range Contraction | -2.48% | |
Narrow Range Bar | Range Contraction | -2.48% | |
BB Squeeze Started | Range Contraction | -2.48% |
Alert | Time |
---|---|
Lower Bollinger Band Support | about 23 hours ago |
20 DMA Resistance | about 24 hours ago |
10 DMA Resistance | about 24 hours ago |
Up 3% | about 24 hours ago |
Fell Below Lower Bollinger Band | about 24 hours ago |
Get this analysis on your stocks daily!
- Earnings date: 03/28/2024
Trevena, Inc. Description
Trevena, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing therapeutics for G protein coupled receptors. Its products include TRV027 that has completed Phase 2a clinical trials for the treatment of acute heart failure; TRV130, a small molecule G protein biased ligand at the µ-opioid receptor has completed Phase 1b clinical trials to treat moderate to severe acute pain intravenously; TRV734 that is in preclinical studies as a orally administered treatment of moderate to severe acute and chronic pain; and d-opioid receptor G protein biased ligand therapeutics for the treatment of central nervous system disorders. The company was formerly known as Parallax Therapeutics, Inc. and changed its name to Trevena, Inc. in January 2008. Trevena, Inc. was founded in 2007 and is based in King of Prussia, Pennsylvania.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Pain Organic Compounds Opioids Heart Failure Chronic Pain Central Nervous System Disorders Nervous System Disorders Signal Transduction Analgesics Acute Pain Pyridines Cell Signaling Treatment Of Central Nervous System Disorders Acute And Chronic Pain Opioid Receptors
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 3.28 |
52 Week Low | 0.5084 |
Average Volume | 106,436 |
200-Day Moving Average | 0.73 |
50-Day Moving Average | 0.62 |
20-Day Moving Average | 0.57 |
10-Day Moving Average | 0.56 |
Average True Range | 0.04 |
RSI (14) | 41.52 |
ADX | 23.55 |
+DI | 15.46 |
-DI | 10.14 |
Chandelier Exit (Long, 3 ATRs) | 0.59 |
Chandelier Exit (Short, 3 ATRs) | 0.65 |
Upper Bollinger Bands | 0.59 |
Lower Bollinger Band | 0.55 |
Percent B (%b) | 0.07 |
BandWidth | 7.36 |
MACD Line | -0.01 |
MACD Signal Line | -0.02 |
MACD Histogram | 0.0005 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 0.58 | ||||
Resistance 3 (R3) | 0.58 | 0.58 | 0.58 | ||
Resistance 2 (R2) | 0.58 | 0.57 | 0.57 | 0.57 | |
Resistance 1 (R1) | 0.56 | 0.56 | 0.56 | 0.56 | 0.57 |
Pivot Point | 0.56 | 0.56 | 0.55 | 0.55 | 0.56 |
Support 1 (S1) | 0.54 | 0.55 | 0.54 | 0.54 | 0.53 |
Support 2 (S2) | 0.53 | 0.54 | 0.53 | 0.53 | |
Support 3 (S3) | 0.52 | 0.53 | 0.52 | ||
Support 4 (S4) | 0.52 |